natgillin/translations-raw huggingface dataset:
The antibody for use according to any one of claims 1 to 9, wherein said subject's pre-administration absolute eosinophil count is about 25, about 50, about 75, about 100, about 125, about 150, about 175, about 200, about 225, about 250, about 275, about 300, about 325, about 350, about 375, about 400, about 450, about 475, or about 500 eosinophils / mm3. 
Protutijelo za upotrebu prema bilo kojem od zahtjeva 1 do 9, naznačeno time da navedeni subjekt ima apsolutni broj eozinofila prije davanja oko 25, oko 50, oko 75, oko 100, oko 125, oko 150, oko 175, oko 200, oko 225, oko 250, oko 275, oko 300, oko 325, oko 350, oko 375, oko 400, oko 450, oko 475, ili oko 500 eozinofila / mm3.
providing at least one ground natural calcium carbonate (GNCC); 
osiguravanje barem jednom prirodnog mljevenog kalcijevog karbonata (GNCC);
contacting said GNCC of step a) with said acid of step b) and with said CO2 of step c); 
kontaktiranje navedenog GNCC iz koraka a) s navedenom kiselinom iz koraka b) i s navedenim CO2 iz koraka c);
said acid(s) of step b) each having a pKa of greater than 2.5 and less than or equal to 7, when measured at 20°C, associated with the ionisation of their first available hydrogen, and a corresponding anion formed on loss of this first available hydrogen capable of forming water-soluble calcium salts; 
navedena kiselina(e) iz koraka b) koja svaka ima pKa veći od 2.5 i manji od ili jednak 7, mjereno na 20°C, povezana je s ionizacijom njezinog prvog slobodnog vodika, te odgovarajući anion stvoren gubitkom tog prvog slobodnog vodika može tvoriti u vodi topive kalcijeve soli i pri čemu se navedena u vodi topiva kiselina(e) odabire iz skupine koju čine octena kiselina, mravlja kiselina, propanska kiselina i njihove smjese;
following contacting said acid(s) with said GNCC, at least one water-soluble salt, which in the case of a hydrogen-containing salt has a pKa of greater than 7, when measured at 20°C, associated with the ionisation of the first available hydrogen, and the salt anion of which is capable of forming water-insoluble calcium salts, is additionally provided; 
nakon kontaktiranja navedene kiseline ili kiselina s navedenim GNCC, dodatno se osigurava barem jedna vodi topiva sol, koja je u slučaju soli koja sadrži vodik ima pKa veći od 7, mjereno na 20°C, povezana s ionizacijom prvog slobodnog vodika, te anionom soli koja može tvoriti u vodi ne-topive kalcijeve soli;
Process according to claim 1, characterized in that said GNCC is selected from the group consisting of marble, chalk, calcite, dolomite, limestone and mixtures thereof. 
Vodena suspenzija prema zahtjevu 1, naznačena time da je navedeni GNCC odabran iz skupine koja sadrži mramor, kredu, kalcit, dolomit, vapnenac i njihove smjese.
Process according to any of claims 1 to 7, characterized in that said water-soluble acid(s) are selected from the group consisting of acetic acid, formic acid, propanoic acid and mixtures thereof, more preferably are selected from the group consisting of acetic acid, formic acid and mixtures thereof, and most preferably is acetic acid. 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 7, naznačena time da je navedena u vodi topiva kiselina(e) odabrana iz skupine koja sadrži octenu kiselinu, mravlju kiselinu i njihove smjese, te je poželjno octena kiselina.
Process according to any of claims 1 to 9, characterized in that said water-soluble acid(s) of step b) are dosed in a total amount corresponding to 5 to 40 wt.-% equivalent pure acid based on the dry weight of GNCC provided in step a), more preferably in a total amount corresponding to 10 to 30 wt.-% equivalent pure acid based on the dry weight of GNCC provided in step a), and most preferably in a total amount corresponding to 15 to 25 wt.-% equivalent pure acid based on the dry weight of GNCC provided in step a). 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 9, naznačena time da se navedena u vodi topiva kiselina(e) iz koraka b) dozira u ukupnoj količini koja odgovara 5 do 40 tež.-% ekvivalenata čiste kiseline bazirano na težini suhog GNCC osiguranog u koraku a), poželjnije u ukupnoj količini koja odgovara od 10 do 30 tež.-% ekvivalenata čiste kiseline bazirano na težini suhog GNCC osiguranog u koraku a), te najpoželjnije u ukupnoj količini koja odgovara od 15 do 25 tež.-% ekvivalenata čiste kiseline bazirano na težini suhog GNCC osiguranog u koraku a).
Process according to any of claims 1 to 11, characterized in that said water-soluble acid(s) of step b) are provided in the form of an aqueous solution having an acid concentration, determined as the equivalent weight of pure acid on the weight of the total solution, corresponding to from 25 to 75 %, and more preferably to from 40 to 60 %. 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 10, naznačena time da se navedena u vodi topiva kiselina(e) iz koraka b) osigurava u obliku vodene otopine koja ima kiselu koncentraciju, određenu kao ekvivalentna težina čiste kiseline prema težini ukupne otopine, koja odgovara od 25 do 75 %, te poželjnije od 40 do 60 %.
Process according to any of claims 1 to 14, characterized in that the anion of said water-soluble salt is selected from the group consisting of phosphate, dihydrogen phosphate, monohydrogen phosphate, oxalate, silicate, mixtures thereof and hydrates thereof, more preferably from the group consisting of phosphate, dihydrogen phosphate, monohydrogen phosphate, mixtures thereof and hydrates thereof, and most preferably from the group consisting of dihydrogen phosphate, monohydrogen phosphate, mixtures thereof and hydrates thereof. 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 13, naznačena time da da je anion navedene soli koja je topiva u vodi odabran iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, oksalat, silikat, njihove smjese i njihove hidrate, poželjnije iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, njihove smjese i njihove hidrate, te je najpoželjnije iz skupine koja sadrži dihidrogen fosfat, monohidrogen fosfat, njihove smjese i njihove hidrate.
Process according to any of claims 1 to 15, characterized in that the anion of said water-soluble salt(s) is dosed in a total amount corresponding to at least 5 x 10-5 mol of anion/m2 GNCC provided in step a), preferably in a total amount corresponding to 5 x 10-5 to 50 x 10-5 mol of anion/m2 GNCC provided in step a), and more preferably in a total amount corresponding to 10 x 10-5 to 30 x 10-5 mol of anion/m2 GNCC provided in step a). 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 14, naznačena time da se anion navedene u vodi topive soli ili topivih soli dozira u ukupnoj količini koja odgovara barem 5 x 10-5 mol anion/m2 GNCC osiguranog u koraku a), poželjno u ukupnoj količini koja odgovara 5 x 10-5 do 50 x 10-5 mol anion/m2 GNCC osiguranog u koraku a), te poželjnije u ukupnoj količini koja odgovara 10 x 10-5 do 30 x 10-5 mol anion/m2 GNCC osiguranog u koraku a).
The carrier peptide of claim 1, wherein each X is independently chosen from arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, threonine, and tyrosine, or wherein n is chosen from 4, 8, 12, 16, and 20, or wherein m is 1. 
Peptid nosač prema zahtjevu 1, naznačen time da svaki X je neovisno odabran od arginina, asparagina, asparaginske kiseline, glutaminske kiseline, glutamina, histidina, lizina, serina, treonina, i tirozina, ili pri čemu n je odabran od 4, 8, 12, 16, i 20, ili pri čemu m je 1.
The carrier peptide of claim 1, wherein the polypeptide is less than 100 amino acids in length. 
Peptid nosač prema zahtjevu 1, naznačen time da polipeptid ima duljinu od manje od 100 amino kiselina.
The complex of claim 5, wherein the biologically active molecule is chosen from a: polypeptide; oligonucleotide; plasmid; small molecule; antibody; antibody fragment; carbohydrate; polysaccharide; lipid; glycolipid; antigen; and antigenic peptide, in particular wherein the oligonucleotide is chosen from a: coding DNA sequence; antisense DNA sequence; mRNA, antisense RNA sequence; RNAi; and siRNA, or wherein the small molecule is a therapeutic agent. 
Kompleks prema zahtjevu 5, naznačen time da biološki aktivna molekula je odabrana od: polipeptida; oligonukleotida; plazmida; male molekule; antitijela; fragmenta antitijela; ugljikohidrata; polisaharida; lipida; glikolipida; antigena; te antigenog peptida, naročito pri čemu je oligonukleotid odabran od: kodirajuće DNA sekvence; anti-sensne DNA sekvence; mRNA, antisense RNA sekvence; RNAi; te siRNA, ili pri čemu mala molekula je terapeutsko sredstvo.
The complex of claim 5, wherein the biologically active molecule or imaging agent is non-covalently bound to the carrier peptide. 
Kompleks prema zahtjevu 5, naznačen time da je biološki aktivna molekula ili kontrastno sredstvo ne-kovalentno vezano na peptid nosač.
A method of producing a heavy chain-only antibody which binds specifically to an antigen comprising: 
Postupak dobivanja antitijela koja sadrže samo teški lanac koje se specifično veže na antigen koji sadrži:
immunising a non-human transgenic mammal with the antigen, wherein the mammal expresses heavy chain-only antibodies which lack a CH1 domain in the transcribed and processed heavy chain mRNA, and wherein the heavy chain-only antibodies are expressed from a transgenic locus in the mammal; 
imuniziranje ne-humanog transgenog sisavca s antigenom, pri čemu sisavac eksprimira antitijela koja sadrže samo teški lanac kojima nedostaje CH1 domena u transkribiranoj i obrađenoj mRNA teškog lanca, te pri čemu su antitijela koja sadrže samo teški lanac eksprimirana iz transgenog lokusa sisavca;
isolating long-lived plasma cells or memory B-cells from the immunised mammal; 
izoliranje dugovječnih stanica plazme ili memorijskih B-stanica iz imuniziranog sisavca;
isolating an mRNA population from cells derived from step (b); 
izoliranje mRNA populacije iz stanica dobivenih u koraku (b);
cloning a cDNA population derived from the mRNA isolated in step (c) into an expression vector and expressing the expression vector in a cell-line; and 
kloniranje cDNA populacije dobivene iz mRNA izolirane u koraku (c) u ekspresijski vektor i eksprimiranje ekspresijskog vektora u staničnoj liniji; te
selecting at least one cell-line which produces a heavy chain-only antibody which binds specifically to the antigen, wherein the mammal is a mouse or a rat. 
odabir barem jedne stanične linije koja proizvodi antitijelo koje sadrži samo teški lanac koje se specifično veže na antigen, pri čemu je sisavac miš ili štakor.
A method of producing a soluble VH domain or a VH fusion protein which binds specifically to an antigen comprising: 
Postupak dobivanja topive VH domene ili VH fuzijskog proteina koji se specifično veže na antigen koji sadrži:
selecting at least one cell-line which produces a VH domain or a VH fusion protein which binds specifically to the antigen, wherein the mammal is a mouse or a rat. 
odabir barem jedne stanične linije koja proizvodi VH domenu ili VH fuzijski protein koji se specifično veže na antigen, pri čemu je sisavac miš ili štakor.
The method of claim 1 or claim 2, wherein the antigen-challenged, non-human transgenic mammal is a mouse, and the long-lived plasma cells or memory B-cells are purified from the secondary lymph glands, bone marrow or spleen of the mouse. 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time da antigenom izazvan, ne-humani transgeni sisavac je miš, a dugovječne plazma stanice ili memorijske B-stanice su pročišćene iz sekundarnih limfnih čvorova, koštane srži ili slezene miša.
The method of any one of claims 1 to 6, wherein step (d) comprises transfecting said expression vector into bacteria in a high throughput automatable format, amplifying said bacteria, isolating the expression vector and transfecting the expression vector into expression cells. 
Postupak prema bilo kojem od zahtjeva 1 do 6, naznačen time da korak (d) sadrži transfekciju navedenog ekspresijskog vektora u bakteriju u visoko propusnom automatizirajućem formatu, pojačavanje navedene bakterije, izolaciju ekspresijskog vektora i transfekciju ekspresijskog vektora u eksprimirane stanice.
The method of any one of claims 1 to 11, further including the step of isolating either a soluble VH domain or a nucleic acid encoding a soluble VH domain from a heavy chain-only antibody-producing cell produced by the mammal or from an immortalised heavy chain-only antibody or VH fusion protein producing cell produced by the mammal by a display approach. 
Postupak prema bilo kojem od zahtjeva 1 do 11, naznačen time da sadrži korak izoliranja bilo topive VH domene ili nukleinske kiseline koja kodira topivu VH domenu iz stanice antitijela koje proizvodi samo težak lanac dobivenu od sisavca ili iz imortaliziranog antitijela koje sadrži samo teški lanac ili VH fuzijskog proteina koji proizvodi stanicu dobivenu od sisavca pristupom prikaza.
The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R is a fluorobutyl group, a pentyl group, a cyclohexyl group, a difluorocyclohexyl group, a cyclopentenyl group or a cyclohexenyl group. 
Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time da R je fluorobutil skupina, pentil skupina, cikloheksil skupina, difluorocikloheksil skupina, ciklopentenil skupina ili cikloheksenil skupina.
The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein Z is a chlorine atom, a methyl group, a difluoromethyl group or a trifluoromethyl group. 
Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 4, naznačen time da Z je atom klora, metilna skupina, difluorometilna skupina ili trifluorometilna skupina.
A compound according to claim 1, which is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koju čine:
Can end lid according to claim 2, wherein the ring bead (15) is surrounded along the breaking-away area (7) by an area (19) that is sloped correspondingly to the upper surface of the pedestal elevation (18). 
Poklopac limenke u skladu s patentnim zahtjevom 7, naznačen time što ploča poklopca (2) uključuje područje (19) koje okružuje prstenastu stijenku (11), koja je tako nagnuta da odgovara gornjoj površini podloge uzvišenja (18).
L', L", and L"' are the same or different, and are independently selected from -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit -(OCH2CH2)n-Rc, halogen, guanidinium [-NH(C=NH)NH2], -OR, -NR'R", -NO2, -NR'COR", -SR, a sulfoxide represented by -SOR', a sulfone represented by -SO2R', a sulfonate - SO3M, a sulfate -OSO3M, a sulfonamide represented by -SO2NR'R", cyano, an azido, -COR', -OCOR', -OCONR'R"; M is -H or a pharmaceutically acceptable cation; and, G is selected from -CH- or -N-. 
L', L" i L"' su jednaki ili različiti, i nezavisno su izabrani između -H, po izboru supstituirani linearni, razgranati ili ciklički alkil, alkenil ili alkinil s 1 do 10 atoma ugljika, jedinica polietilen glikola (-OCH2CH2)n-Rc, halogen, gvanidin [-NH(C=NH)NH2], -OR, -NR'R", -NO2, -NR'COR", -SR, sulfoksid predstavljen s -SOR', sulfon predstavljen s -SO2R', sulfonat -SO3M, sulfat -OSO3M, sulfonamid predstavljen s -SO2NR'R", cijano, azid, -COR', -OCOR', -OCONR'R" i vezna skupina s vezanom reaktivnom skupinom na sebi; uz uvjet da je samo jedan od L', L" i L"' vezna skupina s vezanom reaktivnom skupinom; i G je izabran između -CH- ili -N-.
A process for manufacturing coated substrates, characterized by the steps: 
Postupak za proizvodnju obložene podloge, koji sadrži korake:
coating the substrate with the at least one mineral material to obtain a pre-coat layer of mineral material, 
oblaganje podloge s barem jednim mineralnim materijalom da se dobije sloj pred-obloge od mineralnog materijala,
The method according to claim 1, characterized in that the substrate is selected from the group comprising papers and boards, such as calendered and uncalendered, coated and uncoated papers and boards; synthetic papers; non-woven products; packaging material; constructional materials such as decorative papers and paperboard; and surface finishings. 
Postupak prema zahtjevu 1,naznačen time da je podloga odabrana iz skupine koju čine papiri i kartoni, kao što su kalandrirani i nekalandrirani, obloženi i neobloženi papiri i kartoni; sintetski papiri; netkani proizvodi; materijal za pakiranje; konstrukcijski materijali kao što su dekorativni papiri i papirnati karton; te završne obrade površine.
The method according to claims 1 or 2, characterized in that said mineral material is selected from the group comprising mineral pigments and/or fillers, preferably from the group comprising precipitated calcium carbonate (PCC); natural ground calcium carbonate (GCC); surface modified calcium carbonate; dolomite; talc; bentonite; clay; magnesite; satin white; sepiolite, huntite, diatomite; silicates; titanium dioxide; and mixtures thereof. 
Postupak prema zahtjevima 1 ili 2,naznačen time da je navedeni mineralni materijal odabran iz skupine koju čine mineralni pigmenti i/ili punila, poželjno iz skupine koju čine istaloženi kalcijev karbonat (PCC); prirodni usitnjeni kalcijev karbonat (GCC); površinski modificiran kalcijev karbonat; dolomit; talk; bentonit; glina; magnezit; bijeli satin; sepiolit, huntit, dijatomit; silikati; titanijev dioksid; te njihove smjese.
The method according to claim 3, characterized in that said mineral material is selected from surface-modified calcium carbonates being a reaction product of natural calcium carbonate with carbon dioxide and one or more acids, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source. 
Postupak prema zahtjevu 3,naznačen time da je navedeni mineralni materijal odabran od površinski modificiranih kalcijevih karbonata koji su reakcijski produkt prirodnog kalcijevog karbonata s ugljikovim dioksidom i jednom ili više kiselina, pri čemu je ugljikov dioksid nastao in situ obradom s kiselinom i/ili se dobavlja iz vanjskog izvora.
The method according to claim 3, characterized in that said mineral material is selected from surface-modified calcium carbonates being a reaction product of a PCC-comprising pigment with H3O+ ions and with at least one anion being capable of forming water-insoluble calcium salts, said anion being solubilised in an aqueous medium to form a slurry of surface-reacted PCC-comprising pigment, wherein said surface-reacted PCC comprises an insoluble, at least partially crystalline calcium salt of said anion formed on the surface of at least part of the PCC, and an excess of solubilised calcium ions is provided. 
Postupak prema zahtjevu 3,naznačen time da je navedeni mineralni materijal odabran od površinski modificiranih kalcijevih karbonata koji su reakcijski produkt PCC koji sadrži pigment s H3O+ ionima i s barem jednim anionom koji može tvoriti u vodi netopive kalcijeve soli, te je navedeni anion otopljen u vodenom mediju tako da tvori gustu kašu površinski reaktivnog PCC koji sadrži pigment, pri čemu navedeni površinski reaktivni PCC sadrži netopivu, barem djelomično kristalnu kalcijevu sol navedenog aniona koja se stvara na površini barem dijela PCC, te je osiguran suvišak otopljenih kalcijevih iona.
The method according to any one of the preceding claims, characterized in that said mineral material has a median particle size of from 0.01 to 50 µm, more preferably from 0.05 to 25 µm, even more preferably 0.1 to 10 µm, especially preferably from 0.2 to 5 µm, e.g. 
Postupak prema bilo kojem od prethodnih zahtjeva,naznačen time da navedeni mineralni materijal ima srednju veličinu čestica od 0.01 do 50 µm, poželjnije od 0.05 do 25 µm, čak još poželjnije od 0.1 do 10 µm, naročito poželjno od 0.2 do 5 µm, npr.
The method according to any one of the preceding claims, characterized in that said mineral material is provided in the form of an aqueous suspension having a solids content of is from 10 to 80 wt%, more preferably is from 20 to 75 wt%, even more preferably is from 30 to 60 wt%, most preferably is from 40 to 55 wt%, e.g. 
Postupak prema bilo kojem od prethodnih zahtjeva,naznačen time da je navedeni mineralni materijal osiguran u obliku vodene suspenzije koja ima udjel krutih tvari od 10 do 80 tež.%, poželjnije od 20 do 75 tež.%, čak još poželjnije od 30 do 60 tež.%, najpoželjnije od 40 do 55 tež.%, npr.
The method according to claims 11 or 12, characterized in that said the filler and/or pigment is selected from the group comprising precipitated calcium carbonate (PCC), natural ground calcium carbonate (GCC), surface modified calcium carbonate; dolomite; talc; bentonite; clay; magnesite; satin white; sepiolite, huntite, diatomite; silicates; and mixtures thereof; and preferably is selected from the group of precipitated calcium carbonate having vateritic, calcitic or aragonitic crystal structure, especially ultrafine discrete prismatic, scalenohedral or rhombohedral precipitated calcium carbonate; natural ground calcium carbonate being selected from marble, limestone and/or chalk; and mixtures thereof, and preferably have a median particle size of from 0.01 to 15 µm, preferably 0.1 to 10 µm, more preferably 0.3 to 5 µm, especially from 0.5 to 4 µm and most preferably 0.7 to 3.2 µm, e.g. 
Postupak prema zahtjevima 11 ili 12,naznačen time da je navedeno punilo i/ili pigment odabrano iz skupine koja sadrži istaloženi kalcijev karbonat (PCC), prirodni usitnjeni kalcijev karbonat (GCC), površinski modificirani kalcijev karbonat; dolomit; talk; bentonit; glinu; magnezit; bijeli satin; sepiolit, huntit, dijatomit; silikate; te njihove smjese; a poželjno je odabran iz skupine koju čine istaloženi kalcijev karbonat koji ima vateritnu, kalcitnu ili aragonitnu kristalnu strukturu, naročito ultrafini diskretni prizmatični, skalenohedralni ili rombohedralni taložni kalcijev karbonat; prirodni usitnjeni kalcijev karbonat koji je odabran od mramora, vapnenca i/ili krede; te njihove smjese, a poželjno ima srednju veličinu čestica od 0.01 do 15 µm, poželjno 0.1 do 10 µm, poželjnije 0.3 do 5 µm, naročito poželjno od 0.5 do 4 µm i najpoželjnije je 0.7 do 3.2 µm, npr.
The method according to claim 14, characterized in that said at least one further filler and/or pigment has a median particle size of from 0.01 to 5 µm, preferably 0.05 to 1.5 µm, more preferably 0.1 to 0.8 µm and most preferably 0.2 to 0.5 µm, e.g. 
Postupak prema zahtjevu 14,naznačen time da navedeno barem jedno dodatno punilo i/ili pigment ima srednju veličinu čestica od 0.01 do 5 µm, poželjno 0.05 do 1.5 µm, poželjnije 0.1 do 0.8 µm i najpoželjnije 0.2 do 0.5 µm, npr.
The method according to any one of the preceding claims, characterized in that the mineral material as well as the polysaccharide material comprising one or more polysaccharides are independently from each other coated onto the substrate and/or the mineral material pre-coat, respectively, in one or several layers. 
Postupak prema bilo kojem od prethodnih zahtjeva,naznačen time da su mineralni materijal kao i polisaharidni materijal koji sadrži jedan ili više polisaharida međusobno neovisno prevučeni u jednom ili nekoliko slojeva na odgovarajuću podlogu i/ili pred-oblogu mineralnog materijala.
The method according to any one of the preceding claims, characterized in that the total coat weight of the mineral material pre-coat is from 2 gm-2 to 50 gm-2, preferably from 5 gm-2 to 40 gm-2, more preferably from 7 gm-2 to 30 gm-2 most preferably from 8 gm-2 to 25 gm-2. 
Postupak prema bilo kojem od prethodnih zahtjeva,naznačen time da je ukupna težina obloge pred-obloge od mineralnog materijala od 2 gm-2 do 50 gm-2, poželjno od 5 gm-2 do 40 gm-2, poželjnije od 7 gm-2 do 30 gm-2 najpoželjnije od 8 gm-2 do 25 gm-2.
The coated substrate according to claims 19 or 20, characterized in that one part of the polysaccharide material covers the mineral material, whereas the rest of the polysaccharide material is absorbed into the mineral material pre-coat. 
Obložena podloga prema zahtjevima 19 ili 20, naznačena time da jedan dio polisaharidnog materijala prekriva mineralni materijal, pri čemu je ostatak polisaharidnog materijala apsorbiran u pred-oblogu mineralnog materijala.